• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞周期蛋白D1过表达在乳腺癌中的预后价值测定。

Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

作者信息

McIntosh G G, Anderson J J, Milton I, Steward M, Parr A H, Thomas M D, Henry J A, Angus B, Lennard T W, Horne C H

机构信息

Department of Pathology, Royal Victoria Infirmary, University of Newcastle upon Tyne, UK.

出版信息

Oncogene. 1995 Sep 7;11(5):885-91.

PMID:7675447
Abstract

Cyclin D1 plays a critical role in the timing of the initiation of DNA synthesis in the normal cell cycle of mammalian cells. Deregulated expression of this protein has been seen in a variety of tumours either as a result of gene amplification or chromosomal translocation, in breast cancer and B cell malignancies respectively. In order to determine the role this putative oncoprotein plays in breast cancer, we have applied a new monoclonal antibody, recently produced in our laboratory, in an immunohistochemical study of 93 primary breast carcinomas. We show that approximately 28% of the cases displayed enhanced expression of the cyclin D1 protein. Furthermore, either cyclin D1, cyclin D3, or both, were expressed in 69% of cases, suggesting that overexpression of any one member of this family may relieve cancer cells of their mitogenic stimulatory requirement. In addition, we show that those patients whose breast cancers co-express cyclin D1 with either epidermal growth factor receptor (EGFR) or the retinoblastoma protein (pRB) have a significantly poorer prognosis in comparison to those expressing cyclin D1 alone. Our observations indicate that, in a subset of breast cancers, aberrant cyclin D1 expression is a contributory factor to tumorigenesis and in association with EGFR or pRB expression, identify those tumours which may require more aggressive therapy.

摘要

细胞周期蛋白D1在哺乳动物细胞正常细胞周期中DNA合成起始的时间调控方面发挥着关键作用。在多种肿瘤中均可见到该蛋白的表达失调,分别是由于基因扩增或染色体易位所致,在乳腺癌和B细胞恶性肿瘤中表现各异。为了确定这种假定的癌蛋白在乳腺癌中所起的作用,我们应用了一种最近在我们实验室制备的新型单克隆抗体,对93例原发性乳腺癌进行了免疫组织化学研究。我们发现,约28%的病例显示细胞周期蛋白D1蛋白表达增强。此外,69%的病例中细胞周期蛋白D1或细胞周期蛋白D3,或两者均有表达,这表明该家族中任何一个成员的过表达都可能使癌细胞不再需要有丝分裂刺激。此外,我们还发现,与仅表达细胞周期蛋白D1的患者相比,乳腺癌同时表达细胞周期蛋白D1与表皮生长因子受体(EGFR)或视网膜母细胞瘤蛋白(pRB)的患者预后明显更差。我们的观察结果表明,在一部分乳腺癌中,异常的细胞周期蛋白D1表达是肿瘤发生的一个促成因素,并且与EGFR或pRB表达相关,可识别出那些可能需要更积极治疗的肿瘤。

相似文献

1
Determination of the prognostic value of cyclin D1 overexpression in breast cancer.细胞周期蛋白D1过表达在乳腺癌中的预后价值测定。
Oncogene. 1995 Sep 7;11(5):885-91.
2
Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein.乳腺癌中细胞周期蛋白E和D1的失调与视网膜母细胞瘤蛋白的失活有关。
Oncogene. 1997 Jan 23;14(3):295-304. doi: 10.1038/sj.onc.1200833.
3
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.通过免疫组织化学染色检测乳腺癌中细胞周期蛋白D1的扩增和过表达。
Cancer Res. 1994 Apr 1;54(7):1812-7.
4
Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein.人细胞周期蛋白D1的细胞周期相关变异及组织特异性表达
J Pathol. 1994 Mar;172(3):237-45. doi: 10.1002/path.1711720303.
5
Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.细胞周期蛋白D1(PRAD1)在乳腺癌中的蛋白表达:约三分之一的浸润性乳腺癌显示细胞周期蛋白D1癌基因过表达。
Mod Pathol. 1995 Jun;8(5):560-7.
6
Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.人胰腺导管癌及细胞系中RB1和细胞周期蛋白D1的分子与免疫化学分析
Mol Carcinog. 1996 Feb;15(2):85-95. doi: 10.1002/(SICI)1098-2744(199602)15:2<85::AID-MC1>3.0.CO;2-Q.
7
Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression.大鼠成纤维细胞中细胞周期蛋白D1的过表达会导致生长控制、细胞周期进程和基因表达异常。
Oncogene. 1993 Dec;8(12):3447-57.
8
Cyclin D1 overexpression in primary hypopharyngeal carcinomas.原发性下咽癌中细胞周期蛋白D1的过表达
Cancer. 1996 Aug 1;78(3):390-5. doi: 10.1002/(SICI)1097-0142(19960801)78:3<390::AID-CNCR2>3.0.CO;2-O.
9
Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.中国乳腺癌患者细胞周期蛋白D1的改变及其与Ki-67、视网膜母细胞瘤蛋白(pRb)和p53的相关性。
Arch Med Res. 2007 Nov;38(8):846-52. doi: 10.1016/j.arcmed.2007.06.004. Epub 2007 Aug 2.
10
Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.细胞周期蛋白D1在浸润性乳腺癌中的表达。相关性及预后价值。
Am J Pathol. 1997 Feb;150(2):705-11.

引用本文的文献

1
KCNN1 promotes proliferation and metastasis of breast cancer via ERLIN2-mediated stabilization and K63-dependent ubiquitination of Cyclin B1.KCNN1 通过 ERLIN2 介导的 Cyclin B1 稳定化和 K63 依赖性泛素化促进乳腺癌的增殖和转移。
Carcinogenesis. 2023 Dec 30;44(12):809-823. doi: 10.1093/carcin/bgad070.
2
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.癌组织中细胞周期蛋白 D1 剪接异常:从分子机制到治疗调控。
Cell Death Dis. 2023 Apr 6;14(4):244. doi: 10.1038/s41419-023-05763-7.
3
CDK4: a master regulator of the cell cycle and its role in cancer.
细胞周期蛋白依赖性激酶4(CDK4):细胞周期的主要调节因子及其在癌症中的作用。
Genes Cancer. 2022 Aug 25;13:21-45. doi: 10.18632/genesandcancer.221. eCollection 2022.
4
Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.炎症小体通路的下游信号在不同分子亚型乳腺癌背景下影响患者预后。
Pharmaceuticals (Basel). 2022 May 24;15(6):651. doi: 10.3390/ph15060651.
5
Novel B, C-ring truncated deguelin derivatives reveals as potential inhibitors of cyclin D1 and cyclin E using molecular docking and molecular dynamic simulation.新型 B、C 环截断去甲二氢愈创木酸衍生物通过分子对接和分子动力学模拟显示为细胞周期蛋白 D1 和细胞周期蛋白 E 的潜在抑制剂。
Mol Divers. 2022 Aug;26(4):2295-2309. doi: 10.1007/s11030-021-10334-z. Epub 2021 Oct 9.
6
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.CDK4/6抑制剂在乳腺癌中的临床及药理学差异
Front Oncol. 2021 Jul 12;11:693104. doi: 10.3389/fonc.2021.693104. eCollection 2021.
7
Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma.t(11;22)导致 3' CCND1 截断,从而使 blastoid 套细胞淋巴瘤的 SP4 CCND1 免疫组化呈阴性。
Blood Adv. 2021 Jan 12;5(1):61-65. doi: 10.1182/bloodadvances.2020003417.
8
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.乳腺癌中 CDK4/6 抑制剂策略及联合治疗的最新进展。
Cells. 2019 Apr 6;8(4):321. doi: 10.3390/cells8040321.
9
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.转移性乳腺癌中频繁出现 ESR1 和 CDK 通路拷贝数改变。
Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. Epub 2018 Oct 24.
10
Cell Cycle Regulation by Alternative Polyadenylation of CCND1.CCND1 的可变多聚腺苷酸化对细胞周期的调控。
Sci Rep. 2018 May 1;8(1):6824. doi: 10.1038/s41598-018-25141-0.